Maxigen Biotech Inc Total Liabilities
Maxigen Biotech Inc total liabilities. Based on the latest financial reports, Maxigen Biotech Inc (1783) has total liabilities worth NT$534.02 Million TWD (≈ $16.82 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Maxigen Biotech Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Maxigen Biotech Inc (2009–2025)
Total liabilities of Maxigen Biotech Inc from 2009 to 2025. This chart illustrates how Maxigen Biotech Inc's total liabilities have evolved over time, based on quarterly financial data.
Maxigen Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Maxigen Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TMT Investments PLC
LSE:TMT
|
UK | $661.36K |
|
Dyaco International Inc
TW:1598
|
Taiwan | NT$5.20 Billion |
|
CO2 Energy Transition Corp. Common Stock
NASDAQ:NOEM
|
USA | $2.69 Million |
|
Excel Cell Electronic Co Ltd
TW:2483
|
Taiwan | NT$1.72 Billion |
|
Ester Industries Limited
NSE:ESTER
|
India | Rs8.91 Billion |
|
Scientex Packaging
KLSE:8125
|
Malaysia | RM179.73 Million |
|
HomesToLife Ltd
NASDAQ:HTLM
|
USA | $75.56 Million |
|
Serrano 61 Desarrollo SOCIMI SA
MC:YSRR
|
Spain | €36.97 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Maxigen Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Maxigen Biotech Inc (1783) total assets.
Liquidity & Leverage Metrics
Maxigen Biotech Inc Total Liabilities Ratios Explained
Maxigen Biotech Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Maxigen Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Maxigen Biotech Inc (2009–2025)
The table below shows the annual total liabilities of Maxigen Biotech Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$355.54 Million ≈ $11.20 Million |
+71.46% |
| 2024-12-31 | NT$207.36 Million ≈ $6.53 Million |
+57.23% |
| 2023-12-31 | NT$131.88 Million ≈ $4.16 Million |
-13.27% |
| 2022-12-31 | NT$152.07 Million ≈ $4.79 Million |
+23.16% |
| 2021-12-31 | NT$123.47 Million ≈ $3.89 Million |
+28.29% |
| 2020-12-31 | NT$96.24 Million ≈ $3.03 Million |
-71.20% |
| 2019-12-31 | NT$334.17 Million ≈ $10.53 Million |
+14.25% |
| 2018-12-31 | NT$292.48 Million ≈ $9.21 Million |
-4.96% |
| 2017-12-31 | NT$307.73 Million ≈ $9.70 Million |
-2.63% |
| 2016-12-31 | NT$316.04 Million ≈ $9.96 Million |
-6.60% |
| 2015-12-31 | NT$338.38 Million ≈ $10.66 Million |
+147.62% |
| 2014-12-31 | NT$136.65 Million ≈ $4.31 Million |
+8.42% |
| 2013-12-31 | NT$126.04 Million ≈ $3.97 Million |
+4.94% |
| 2012-12-31 | NT$120.10 Million ≈ $3.78 Million |
+2.30% |
| 2011-12-31 | NT$117.40 Million ≈ $3.70 Million |
+241.60% |
| 2010-12-31 | NT$34.37 Million ≈ $1.08 Million |
+12.63% |
| 2009-12-31 | NT$30.51 Million ≈ $961.36K |
-- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more